These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31648992)

  • 41. Identification of Monotonically Differentially Expressed Genes for IFN-
    Tian S; Zhang L
    Biomed Res Int; 2019; 2019():5647902. PubMed ID: 31915697
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inverse Relation between MxA Gene Expression and Age in Multiple Sclerosis Patients Reveals a Gender Difference in Response to Interferon Therapy.
    Taheri M; Mirinezhad M; Omrani MD; Sajjadi E; Inoko H; Sayad A
    Iran J Allergy Asthma Immunol; 2017 Feb; 16(1):21-27. PubMed ID: 28417621
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antagonistic action of IFN-beta and IFN-gamma on high affinity Fc gamma receptor expression in healthy controls and multiple sclerosis patients.
    Van Weyenbergh J; Lipinski P; Abadie A; Chabas D; Blank U; Liblau R; Wietzerbin J
    J Immunol; 1998 Aug; 161(3):1568-74. PubMed ID: 9686625
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Endogenous interferon-β-inducible gene expression and interferon-β-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis.
    Börnsen L; Romme Christensen J; Ratzer R; Hedegaard C; Søndergaard HB; Krakauer M; Hesse D; Nielsen CH; Sorensen PS; Sellebjerg F
    PLoS One; 2015; 10(3):e0118830. PubMed ID: 25738751
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis.
    Pellegrini P; Totaro R; Contasta I; Berghella AM; Carolei A; Adorno D
    Neuroimmunomodulation; 2005; 12(4):220-34. PubMed ID: 15990453
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis.
    Hong J; Zang YC; Hutton G; Rivera VM; Zhang JZ
    J Neuroimmunol; 2004 Jul; 152(1-2):126-39. PubMed ID: 15223245
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interferon-β 1a Modulates Expression of RAGE but Not S100A12 and Nuclear Factor-κB in Multiple Sclerosis Patients.
    Asadikaram G; Noroozi S; Ebrahimi Meimand HA; Sanjari M; Zainodini N; Khoramdelazad H; Shahrokhi N; Kazemi Arababadi M
    Neuroimmunomodulation; 2016; 23(5-6):345-351. PubMed ID: 28433998
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis.
    Marckmann S; Wiesemann E; Hilse R; Trebst C; Stangel M; Windhagen A
    Clin Exp Immunol; 2004 Dec; 138(3):499-506. PubMed ID: 15544628
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
    Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
    Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term use of interferon-β in multiple sclerosis increases Vδ1
    Maimaitijiang G; Watanabe M; Shinoda K; Isobe N; Nakamura Y; Masaki K; Matsushita T; Yoshikai Y; Kira JI
    J Neuroinflammation; 2019 Sep; 16(1):179. PubMed ID: 31519178
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation.
    Cox MB; Bowden NA; Scott RJ; Lechner-Scott J
    Mult Scler; 2013 Sep; 19(10):1268-74. PubMed ID: 23401127
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunoregulatory Effects of Silymarin on Proliferation and Activation of Th1 Cells Isolated from Newly Diagnosed and IFN-ß
    Navabi F; Shaygannejad V; Abbasirad F; Vaez E; Hosseininasab F; Kazemi M; Mirmosayyeb O; Alsahebfosoul F; Esmaeil N
    Inflammation; 2019 Feb; 42(1):54-63. PubMed ID: 30178232
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: implications for control of apoptosis.
    Ahn J; Feng X; Patel N; Dhawan N; Reder AT
    Front Biosci; 2004 May; 9():1547-55. PubMed ID: 14977566
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel interferon-beta-induced gene expression in peripheral blood cells.
    Rani MR; Shrock J; Appachi S; Rudick RA; Williams BR; Ransohoff RM
    J Leukoc Biol; 2007 Nov; 82(5):1353-60. PubMed ID: 17709400
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis.
    Krakauer M; Sorensen PS; Khademi M; Olsson T; Sellebjerg F
    Scand J Immunol; 2006 Aug; 64(2):155-63. PubMed ID: 16867161
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: does baseline T-bet mRNA predict the response to interferon-beta treatment?
    Drulovic J; Savic E; Pekmezovic T; Mesaros S; Stojsavljevic N; Dujmovic-Basuroski I; Kostic J; Vasic V; Mostarica Stojkovic M; Popadic D
    J Neuroimmunol; 2009 Oct; 215(1-2):90-5. PubMed ID: 19695714
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN-beta and IL-10.
    Huang YM; Stoyanova N; Jin YP; Teleshova N; Hussien Y; Xiao BG; Fredrikson S; Link H
    Clin Exp Immunol; 2001 May; 124(2):306-14. PubMed ID: 11422209
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.
    Kulakova OG; Tsareva EY; Lvovs D; Favorov AV; Boyko AN; Favorova OO
    Pharmacogenomics; 2014 Apr; 15(5):679-85. PubMed ID: 24798724
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment.
    Liuzzi GM; Latronico T; Fasano A; Carlone G; Riccio P
    Mult Scler; 2004 Jun; 10(3):290-7. PubMed ID: 15222694
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regulatory effects of interferon-β on osteopontin and interleukin-17 expression in multiple sclerosis.
    Hong J; Hutton GJ
    J Interferon Cytokine Res; 2010 Oct; 30(10):751-7. PubMed ID: 20874252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.